1st Quarter - Report

SOCIETY FOR NEUROSCIENCE for SOCIETY FOR NEUROSCIENCE

Firm
Client
Income
—
Expenses
$128,468
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Education EDU

Communication and outreach concerning the financial impacts of capping facilities and administrative costs to universities and research institutions.

LobbyistCovered position, as disclosed
ALLEN SEGAL —

Contacted: SENATE; Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Natl Institutes of Health (NIH)

Budget/Appropriations BUD

Advocacy efforts related to FY18 and FY19 funding for National Institutes of Health (NIH) and the National Science Foundation (NSF). Additional advocacy efforts to support completion of FY18 appropriations and raising the budget sequestration caps. Communications to the Office of Management and Budget concerning the President's 2019 budget; stating support for continuing brain research as a top national priority as part of overall federal investment in biomedical research and efforts related to BRAIN Initiative.

LobbyistCovered position, as disclosed
ALLEN SEGAL —

Contacted: Natl Institutes of Health (NIH); SENATE; Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Animals ANI

Communication and outreach concerning the responsible use of animal models in biomedical research. Communication to the Food and Drug Administration (FDA) concerning the closure of the FDA's National Center for Topological Research in Arkansas.

LobbyistCovered position, as disclosed
ALLEN SEGAL —

Contacted: Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; SENATE; Office of Management & Budget (OMB); Food & Drug Administration (FDA)

Medical/Disease Research/Clinical Labs MED

Outreach and communication on the over 1,000 neurological and neurodegenerative diseases that affect nearly 100 million Americans. Communication with NIH over the revised definition of "clinical research" and the impacts on basic science.

LobbyistCovered position, as disclosed
ALLEN SEGAL —

Contacted: Natl Institutes of Health (NIH); SENATE; HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Food & Drug Administration (FDA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.